All studies
Phase 3RecruitingInterventionalNCT06750094

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3)

A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

  • Colorectal Neoplasms
I want to take partRefer a patient8 sites in India · 251 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Janssen Research & Development, LLC
Enrolment target
700
Started
12 December 2024
Main results due (estimated)
15 December 2027
Study ends (estimated)
13 April 2029
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
None
Sites
251 · 8 in India
First posted
27 December 2024
Registry updated
3 November 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Have histologically or cytologically confirmed adenocarcinoma of the colon or rectum. Participants must have recurrent, unresectable or metastatic disease
* Determined to have kirsten rat sarcoma viral oncogene/neuroblastoma RAS viral oncogene homolog (KRAS/NRAS), G12, G13 and v-raf murine sarcoma viral oncogene homolog B (BRAF) V600X (X represents any single amino acid change from the original amino acid) wild type status by local and/or central next-generation sequencing (NGS) testing
* Must agree to the submission of fresh or archival tumor tissue post progression from the most recent therapy, if clinically feasible
* Have measurable disease according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1
* Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1
* Participant must have received 1 line of systemic therapy (fluoropyrimidine-based and oxaliplatin-based) for metastatic colorectal cancer (mCRC), with documented radiographic disease progression on or after this line of therapy. Participants can receive anti-VEGF as prior line of therapy

Exclusion Criteria:

* Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening
* Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: amivantamab, cetuximab or bevacizumab or any component of FOLFIRI
* Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is likely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
* Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status who has not received immunotherapy treatments
* Participant with known human epidermal growth factor receptor 2 (HER2)- positive/amplified tumor
* Has prior exposure to irinotecan, any agents that target epidermal growth factor receptor (EGFR) or mesenchymal epithelial transition (MET)

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.

What participants receive

  • Experimental

    Arm A: Amivantamab + FOLFIRI

    Participants will receive amivantamab along with FOLFIRI (consisting of 5-fluorouracil, leucovorin calcium \[folinic acid\] or levoleucovorin, and irinotecan) as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.

    Biological: Amivantamab · Drug: 5-fluorouracil · Drug: Leucovorin calcium/Levoleucovorin · Drug: Irinotecan

  • Active comparator

    Arm B: Cetuximab or Bevacizumab + FOLFIRI

    Participants will receive either cetuximab or bevacizumab along with FOLFIRI as a chemotherapy regimen for 28-days treatment cycles and will continue to receive the treatment until radiographic disease progression or other discontinuation criteria are met.

    Biological: Cetuximab · Biological: Bevacizumab · Drug: 5-fluorouracil · Drug: Leucovorin calcium/Levoleucovorin · Drug: Irinotecan

Interventions

  • AmivantamabBiological

    Also known as JNJ-61186372

    Amivantamab will be administered.

  • CetuximabBiological

    Also known as Erbitux

    Cetuximab will be administered.

  • BevacizumabBiological

    Also known as Avastin

    Bevacizumab will be administered.

  • 5-fluorouracilDrug

    5-fluorouracil will be administered as chemotherapy regimen.

  • Leucovorin calcium/LevoleucovorinDrug

    Also known as Folinic acid

    Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.

  • IrinotecanDrug

    Irinotecan will be administered as chemotherapy regimen.

What the study measures

Primary outcomes

  1. Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)

    PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by BICR using response evaluation criteria in solid tumors (RECIST) version (v)1.1. Participants who have not progressed or have not died at the time of analysis will be censored at their last evaluable RECIST v1.1 assessment date.

    Time frame: Up to 2 years 1 month

  2. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of participant's death due to any cause.

    Time frame: Up to 4 years 4 months

Secondary outcomes

  1. Objective Response Rate (ORR) as Assessed by BICR

    ORR is defined as the percentage of randomized participants achieving partial response (PR) or complete response (CR), as determined by BICR using RECIST v1.1 criteria.

    Time frame: Up to 4 years 4 months

  2. ORR as Assessed by Investigator

    ORR is defined as the percentage of randomized participants achieving partial response (PR) or complete response (CR), as determined by investigator using RECIST v1.1 criteria.

    Time frame: Up to 4 years 4 months

  3. Progression Free Survival as Assessed by Investigator

    PFS is defined as the time from randomization until the date of objective disease progression or death (due to any cause), whichever comes first, as assessed by investigator.

    Time frame: Up to 4 years 4 months

  4. Duration of Response (DoR) as Assessed by BICR

    DoR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR as assessed by BICR.

    Time frame: Up to 4 years 4 months

  5. Duration of Response as Assessed by Investigator

    DoR is defined as time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR as assessed by investigator.

    Time frame: Up to 4 years 4 months

  6. Time to Response (TTR) as Assessed by BICR

    TTR is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression or subsequent systemic anti-cancer therapy or curative-intent procedure, for participants who have PR or CR as BOR, as assessed by BICR.

    Time frame: Up to 4 years 4 months

  7. TTR as Assessed by Investigator

    TTR is defined as the time from the date of randomization to the date of first documentation of a response (PR or CR) prior to any disease progression or subsequent systemic anti-cancer therapy or curative-intent procedure, for participants who have PR or CR as BOR, as assessed by investigator.

    Time frame: Up to 4 years 4 months

  8. Progression Free Survival After Subsequent Therapy (PFS2)

    PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent systemic anticancer therapy, based on investigator assessment or death, whichever comes first.

    Time frame: Up to 4 years 4 months

  9. Disease Control Rate (DCR) as Assessed by BICR

    DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with a minimum duration of 7 weeks) as defined by BICR using RECIST v1.1.

    Time frame: Up to 4 years 4 months

  10. Disease Control Rate as Assessed by Investigator

    DCR is defined as the percentage of randomized participants achieving CR, PR, or stable disease (with a minimum duration of 7 weeks) as assessed by investigator.

    Time frame: Up to 4 years 4 months

  11. Time to Treatment Failure

    Time to treatment failure is defined as time from randomization to discontinuation of therapy for any reason including death, progression, toxicity, or initiation of new anticancer therapy.

    Time frame: Up to 4 years 4 months

  12. Curative Resection (R0) Rate

    Curative resection (R0) rate is defined as the percentage of randomized participants who underwent curative-intent surgery where the residual tumor classification was R0.

    Time frame: Up to 4 years 4 months

  13. Number of Participants with Adverse Events (AEs) by Severity

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE.

    Time frame: Up to 4 years 4 months

  14. Number of Participants with Abnormalities in Laboratory Values

    Participants with abnormalities in laboratory values (such as serum chemistry, hematology) will be reported.

    Time frame: Up to 4 years 4 months

  15. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score

    The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status/quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms.

    Time frame: From baseline up to 4 years 4 months

  16. Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-C30

    Time to worsening in symptoms and functioning as measured by EORTC QLQ-C30 score will be reported. The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms.

    Time frame: Up to 4 years 4 months

  17. Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CR29) Score

    The EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ-CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms.

    Time frame: From baseline up to 4 years 4 months

  18. Time to Worsening in Symptoms and Functioning as Measured by EORTC QLQ-CR29 Score

    Time to worsening in symptoms and functioning as measured by EORTC QLQ-CR29 will be reported. EORTC QLQ-CR29, is a self-administered, 29-item questionnaire measuring the HRQoL of participants with colorectal cancer. The QLQ-CR29 includes items that evaluate symptoms (gastrointestinal, urinary, pain, and others) and functional areas (sexual, body image, weight, and anxiety) that are associated with colorectal cancer and its treatments. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." All scores are linearly converted into a scale from 0 to 100. Higher scores indicate greater functioning and more severe symptoms. Change from baseline in the EORTC QLQ-CR29 score will be reported.

    Time frame: Up to 4 years 4 months

  19. Overall Side Effect Burden as Measured by European Organisation for Research and Treatment of Cancer (EORTC) Item 168 Scale Score

    EORTC item 168 is a single item used to measure the overall impact of treatment side effects. Responses are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much. Higher scores indicates severe symptoms.

    Time frame: Up to 4 years 4 months

Who is running it

Lead sponsor
Janssen Research & Development, LLC
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Janssen Research & Development, LLC
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
61186372COR3002
Other IDs
2024-513853-66-00
  • Janssen Research & Development, LLC Clinical Trial

    Study director

    Janssen Research & Development, LLC

Study sites(251)

  • Rajiv Gandhi Cancer Institute and Research Centre

    Delhi, India

    Recruiting

  • Asian Institute Of Gastroenterology

    Hyderabad, India

    Recruiting

  • B P Poddar Hospital and Medical research Limited

    Kolkata, India

    Recruiting

  • Tata Memorial Hospital

    Mumbai, India

    Recruiting

  • Safdarjung Hospital

    New Delhi, India

    Recruiting

  • Deenanath Mangeshkar Hospital and Research Centre

    Pune, India

    Recruiting

  • Mahamana Pandit Madan Mohan Malviya Cancer Centre

    Varanasi, India

    Recruiting

  • Christian medical

    Vellore, India

    Recruiting

  • Ironwood Cancer and Research Center

    Chandler, Arizona, United States

    Recruiting

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, United States

    Recruiting

  • St. Bernard's Medical Center

    Jonesboro, Arkansas, United States

    Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas, United States

    Recruiting

  • CBCC Global Research

    Bakersfield, California, United States

    Recruiting

  • Los Angeles Cancer Network

    Glendale, California, United States

    Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California, United States

    Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, United States

    Recruiting

  • UCLA

    Santa Monica, California, United States

    Recruiting

  • Providence Medical Foundation

    Santa Rosa, California, United States

    Recruiting

  • Torrance Memorial Physicians Network

    Torrance, California, United States

    Recruiting

  • University of Colorado Denver Anschultz Medical Campus

    Aurora, Colorado, United States

    Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado, United States

    Recruiting

  • Florida Cancer Specialists South

    Fort Myers, Florida, United States

    Recruiting

  • AdventHealth Cancer Institute

    Orlando, Florida, United States

    Recruiting

  • Florida Cancer Specialists North Region

    St. Petersburg, Florida, United States

    Recruiting

  • Florida Cancer Specialists East

    West Palm Beach, Florida, United States

    Recruiting

  • University Cancer And Blood Center LLC

    Athens, Georgia, United States

    Recruiting

  • Grady Memorial Hospital

    Atlanta, Georgia, United States

    Recruiting

  • Piedmont Cancer Institute

    Atlanta, Georgia, United States

    Recruiting

  • Winship Cancer Institute Emory University

    Atlanta, Georgia, United States

    Recruiting

  • Illinois Cancer Specialists

    Arlington Heights, Illinois, United States

    Recruiting

  • Illinois CancerCare

    Peoria, Illinois, United States

    Recruiting

  • Franciscan Health

    Indianapolis, Indiana, United States

    Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, United States

    Recruiting

  • Mission Cancer Blood

    Waukee, Iowa, United States

    Recruiting

  • Cancer Center of Kansas

    Wichita, Kansas, United States

    Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana, United States

    Recruiting

  • MedStar Franklin Square Medical Center

    Baltimore, Maryland, United States

    Recruiting

  • Frederick Health Hospital - James M Stockman Cancer Institute

    Frederick, Maryland, United States

    Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, United States

    Recruiting

  • Henry Ford Hospital

    Detroit, Michigan, United States

    Recruiting

Showing 40 of 251 sites. 235 recruiting, 16 not recruiting and 0 cancelled; 8 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes

The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Source: ClinicalTrials.gov record NCT06750094, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.